- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:24 | Lixte Biotechnology appoints new CFO and board members | 1 | Seeking Alpha | ||
| 25.08. | 24/7 Market News and LIXTE Biotechnology Holdings: 24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets | 6 | GlobeNewswire (USA) | ||
| 19.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the "Too Much of a Good Thing" Strategy for LB-100 | 1 | GlobeNewswire (USA) | ||
| 18.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Provides Corporate Update | 94 | GlobeNewswire (Europe) | -Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory... ► Artikel lesen | |
| 15.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 | 1 | GlobeNewswire (USA) | ||
| 14.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 | 1 | GlobeNewswire (USA) | ||
| 13.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency | 110 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | LIXTE Biotechnology regains Nasdaq compliance | 2 | Seeking Alpha | ||
| 16.07. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements | 245 | GlobeNewswire (Europe) | PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 11.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 09.07. | Lixte Biotechnology Holdings, Inc.: New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials | 10 | GlobeNewswire (USA) | ||
| 08.07. | Lixte Biotechnology raises $1.5 million in registered direct offering | 2 | Investing.com | ||
| 08.07. | Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering | 2 | GlobeNewswire (USA) | ||
| 03.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.07. | Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market | 8 | GlobeNewswire (USA) | ||
| 01.07. | Lixte Biotechnology sichert sich 5 Millionen US-Dollar durch Privatplatzierung | 4 | Investing.com Deutsch | ||
| 01.07. | Lixte Biotechnology secures $5 million in private placement | 1 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,10 | -0,46 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,824 | +0,59 % | SONDERMELDUNG AM MITTWOCH: Evotec-Aktionäre müssen heute dringend handeln, denn sonst ist alles aus und vorbei! | ||
| CRISPR THERAPEUTICS | 45,600 | +0,88 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| INOVIO PHARMACEUTICALS | 2,320 | +4,50 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
| OCUGEN | 0,870 | -1,25 % | Carisma Therapeutics stock soars after merger agreement with Ocugen | ||
| MAINZ BIOMED | 1,690 | +2,42 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Registrierung von ColoAlert im Vereinigten Königreich bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Registrierung von ColoAlert im Vereinigten Königreich bekannt
02.09.2025 / 14:01... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,595 | -0,04 % | Viking Therapeutics Loses 20% in a Month: How to Play the Stock | ||
| IMMUNITYBIO | 2,103 | +3,09 % | ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform | ||
| MARINOMED BIOTECH | 20,000 | +0,50 % | Marinomed Biotech: Einigung über Eckpunkte der Emission einer besicherten Wandelschuldverschreibung | Korneuburg (www.anleihencheck.de) - Marinomed Biotech: Einigung über Eckpunkte der Emission einer besicherten Wandelschuldverschreibung - AnleihenewsDie Marinomed Biotech AG (die "Gesellschaft") (ISIN... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,665 | +0,11 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CEL-SCI | 11,490 | -5,24 % | Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): BUY | Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH
01.09.2025 / 13:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ORAGENICS | 1,050 | +1,45 % | ORAGENICS INC - 8-K, Current Report | ||
| FIBROGEN | 12,300 | +0,99 % | FibroGen stock maintains Buy rating at H.C. Wainwright after China sale | ||
| REVIVE THERAPEUTICS | 0,009 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| CAPRICOR | 5,520 | +1,28 % | Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine | First-in-human trial of Capricor's StealthX vaccine initiated under HHS's Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,280 Euro und damit +3,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.